Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

United Health Products, Inc. (UEEC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.62500.0000 (0.00%)
At close: 03:55PM EST
Advertisement
Sign in to post a message.
  • W
    WHOZURDADDY!!
    HENDERSON, Nev.--(BUSINESS WIRE)--United Health Products, Inc. (OTC: UEEC) (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp, a patented Oxidized Regenerated Cellulose (ORC), today announced that the Journal of Wound Care, headquartered in London, England, has informed the Company that UHP’s submitted article, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, has been accepted for publication in the November 2020 edition. This article, which was peer reviewed, was authored by Raymond Schaerf, MD, Sasan Najibi, MD, John Conrad, MD, and Gerard Abate, MD. This journal submission highlights the results of the study showing HemoStyp’s superiority to Surgicel®, an Ethicon Inc. product, a division of Johnson & Johnson.

    Dr. Gerard Abate, Chief Medical Officer, United Health Products, stated: “This is the first head-to-head trial of two ORCs. The data demonstrates that HemoStyp consistently achieved hemostasis faster than Surgicel in all surgical classes studied in less than two minutes, whereas Surgicel could not and failed to control bleeding in six (6) patients where the control timed out at 10 minutes. Based on the overall data, upon anticipated PMA approval for class III FDA surgical use, surgeons will have a superior product to utilize for low grade surgical bleeds.”
  • V
    VegasValue1
    em 7.01. Regulation FD Disclosure and Other Events.

    As disclosed in recent filings on Form 4, our Chief Executive Officer completed open market sales of a portion of his shares of our common stock. Since his appointment as Chief Executive in December 2020, Mr. Thom has received no cash compensation from the Company and has agreed to accept restricted shares in lieu of cash in payment of some of his accrued compensation. The recent sale of shares was for the purpose of satisfying tax obligations and to cover personal expenses. After giving effect for shares issued to Mr. Thom in 2021 as compensation and the recent sale of shares, Mr. Thom holds 1,368,657 shares of our common stock, an increase of 326,746 shares over his holdings of 1,041,911 shares as of January 1 of this year.
    Bullish
  • W
    WHOZURDADDY!!
    From someone I chat with wrote this. A few people I know ran the numbers and with the outstanding amount of shares, every billion for the sale of the company is about $5 a share. Pharm companies pay 6 billion for companies that have no earning potential compared to this company. You heard Brian mention the military. Surgicrap takes 2 1/2 minutes to stop bleeding. So basically you're dead if you don't have somebody that can stop the bleeding with pressure using that product. This product takes 35 seconds. Once they take over the east coast contracts I can easily see this company getting 8 to 10 billion for the product which would be 40 to $54 a share. The crazy thing is that this product potentially could pay that purchase price off in a couple years. So you can see, $5 to 10 dollars is not happening. I would almost guarantee they have turned that down already as they laughed and hung up the phone.
  • W
    WHOZURDADDY!!
    I say we hear something, within the next 6 weeks. :)
  • G
    Gary
    Who doesn't like a 16% drop in share price? No news till April.
  • E
    Ed
    I too have been waiting for a very long time. I hope that you are correct in your thinking and calculations
    Maybe we will get lucky. I still have 42,500 shares left.
  • k
    kyle
    Looks like this going to stay in the pre approval stage. Seems to people have lost faith and interest in the product.
  • t
    tristan
    United Health Products Announces Positive Results from HemoStyp Human Clinical Trial

    HENDERSON, Nev., Oct. 18, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), (UHP or the Company), manufacturer and marketer of HemoStyp, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,557,874 Oct 15, 2013), for the healthcare and wound care sectors, today announced that it has received the final report from an independent review of the results of its human clinical trial. The review confirmed the non-inferiority and superiority of HemoStyp over Surgicel, the market leader for hemostatic agents.

    In summary the independent statistical reviewer (http://www.stat4ward.com/who_we_are) stated:

    For the primary analysis comparing HemoStyp versus Surgicel for hemostasis in 10 minutes, both non-inferiority and superiority were satisfied in both ITT population and PP population. For the secondary analysis, HemoStyp was significantly better than Surgicel with respect to the percentage achieving hemostasis at 2 minutes, 5 minutes, and 10 minutes.

    The website https://www.clinicaltrials.gov/ct2/show/NCT03654560?term=hemostyp&rank=1 is being updated with all relevant data and supporting documents and will be continuously updated over the next several weeks.

    This trial was conducted on 236 WIRB (Western Institutional Review Board) approved and consented patients. Surgeries consisted of Level 1 and Level 2 bleeds on the Lewis bleeding scale for abdominal, cardiovascular, thoracic and vascular surgeries.

    UHP is continuing its discussions with well positioned candidates interested in acquisition of the Company or partnerships that allow penetration into the surgical markets.

    About United Health Products

    United Health Products develops technology, manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.

    For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

    Safe Harbor Statement

    Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

    Company Contact:
    United Health Products, Inc.
    877-358-3444

    IR Contact :
    PAN Consultants Ltd.
    Philippe Niemetz 212-344-6464 p.niemetz@panconsultants.com

    Source: United Health Products Inc.
    Stat4ward promotes individual excellence and self fulfillment through career success. It provides strong culture for professional growth via mentoring, leadership opportunities, and more importantly, the exposure to a wide variety of exciting consult
    Stat4ward promotes individual excellence and self fulfillment through career success. It provides strong culture for professional growth via mentoring, leadership opportunities, and more importantly, the exposure to a wide variety of exciting consult
    www.stat4ward.com
  • R
    RockJaw
    UEEC is in the home stretch for the 180-day period for review of a PMA application for approval! The one thing that keeps me going with this stock is that almost all of the applications are approved once they have been accepted for the PMA review.
  • W
    WHOZURDADDY!!
    Chop/Connie you are entitled to your own thesis, but I respectively disagree with the study being a “feint.” Current standards of practice in research would not permit institutions like Western Institutional Review Board (WIRB), the well-respected principle investigator, the various surgical medical centers, and the FDA to engage in such a study. UEEC is using WIRB, which is the most respected private IRB in the country that provides guidance and oversight on the ethical quality of a study to ensure patient safety and appropriate data usage. The PI (see the clinicaltrials.gov site) is a nationally recognized surgeon with impeccable academic credentials. Lastly, this is an FDA approved trial, thus the FDA has evaluated the scientific merit and design of the study and likely provided guidance to UEEC on the best trial design for this class of product. With regards to “superiority,” a non-inferiority (NI) trial is often selected over a superiority trial due to ethical reasons-the primary being that using a placebo would place incredible risk to the patient (particularly surgical patients in UEEC’s case). Instead, an NI trial uses an active control condition (Surgicel) to determine if the treatment effects (time to hemostasis) falls within a certain predetermined margin of effectiveness. Depending on the clinical context, NI trials do have their limitations where critique is warranted; however, in the case of surgical trials, and specifically with this UEEC’s trial, it is scientifically and ethically optimal to run a study comparing HemoStyp to an active control (Surgicel) to first determine NI, as a placebo would put surgical patients at significant risk. Once NI is established, one could then run statistics with the current collected data to determine superiority (thus superiority can be tested in NI trials). However, superiority is not required or necessary for product/drug approval from a clinical and scientific standpoint. Also, superiority may not even be related to the primary and secondary outcomes, but rather other factors like cost, safety, feasibility, implementation, etc. Lastly, any comment about UEEC’s product being “old” is unfounded and irrelevant as it is common practice to seek new indications for known products and drugs. A great recent example is ketamine, which is over 50 years old and has been historically used as a horse tranquilizer and continues to be a common anesthetic agent. Ketamine is now being successfully used as a treatment for depression where knowledge leaders in psychiatry believe it could revolutionize care for treatment resistant depression and other psychiatric conditions (NIH is funding a ton a studies on this front)…not bad for an “old” product. UEEC is taking appropriate and legitimate efforts to seek a new FDA approved indication just like Ketamine and the thousands of medications and products that are be repurposed for various indications. See (https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285). In my opinion, it makes practical sense to use a known product for a new indication as it minimizes development costs and overhead, leading to more rapid introduction into clinical care and the market as a whole.
    An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.
    An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.
    www.the-scientist.com
  • R
    RockJaw
    Wow what a bold move to appoint Brian Thom from Société Générale as the new CEO. This guy has done hundreds of billion dollars in M&A projects. Something big is in mix for him to be the CEO for this small company with game changing product. He is a powerhouse in the M&A world and will really help in getting shareholders the best deal in future negotiations for the accusation of this company once FDA approval is completed.
  • R
    RockJaw
    Looks like UHP is moving manufacturing to Strouse they are a 3M Preferred Converter of 3M Medical Materials and Technologies. They also support manufacturing for GE Healthcare, Abbott Laboratories, Medtronic and Teleflex! I bet there is a coloration with this move with a buyer. Good news and great time to pick up more stock.
  • A
    Alexander
    For those having doubts as to the status of the company and their ability to cross the finish line; this was a post from the ihub message board and as a long term shareholder I agree with the logic articulated here:

    This is the money line from the May 5 release: following the resubmission of its application for Pre-market Approval for HemoStyp gauze on April 6th, the FDA has now accepted for review and commenced its Substantive Review of the application.

    Substantive review means the FDA has told UEEC that they now have all they need to proceed, in other words the application is complete. From that point forward the FDA's self imposed deadline to make a decision is 180 days. My belief is that timeline started on May 5, some could argue it started on April 6 but I dont' think so.

    This can't be stated strongly enough, up until that point in time UEEC was only completing the application, people can argue back and forth about what they did or didn't do and how long this has taken, but the bottom line is we are now on the clock.

    My belief is the FDA will make a decision between now and early November, if they don't meet that timeline you can kick and scream about the FDA but unless new information comes out UEEC has done all it can do from an application standpoint.

    Incidentally, reaching a Substantive Review stage is quite an accomplishment in itself, percentage wise very few even reach this stage, and those that do have a very high percentage of acceptance.
  • W
    WHOZURDADDY!!
    I have my 115K shares, will hold till company is sold. :)
  • W
    WHOZURDADDY!!
    Patent protection filed....

    United Health Products Files HemoStyp(R) Hydrocolloid Patents
    8:00 AM ET 7/21/20 | BusinessWire

    HENDERSON, Nev.--(BUSINESS WIRE)--July 21, 2020--

    United Health Products, Inc. (OTC: UEEC) ("UHP" or the "Company"), today announced that it has filed a non-provisional patent application with the U.S. Patent & Trademark Office for the hydrocolloid (gel) format of its HemoStyp oxidized regenerated cellulose product, and has also filed a separate application under the Patent Cooperation Treaty with the World Intellectual Property Organization. The Patent Cooperation Treaty (PCT) is an international patent law treaty which provides a unified procedure for filing of a patent application in the majority of foreign countries. The Company previously filed a provisional patent application for the hydrocolloid technology in July 2019.

    This latest patent application relates to methods of forming and using a hemostatic material and, more specifically, to methods of forming and using a hemostatic gel or foam material to control bleeding and oozing from a variety of wounds. The hemostatic hydrocolloid may be used both outside and inside the body and can be quickly absorbed by the human body when used internally. The coagulation properties of the hemostatic hydrocolloid may accelerate hemostasis. The hemostatic hydrocolloid can be fabricated in various forms to best suit the active bleeding situation, whether from an artery or vein, from internal bleeding during laparoscopic procedures, or on surfaces of bone tissue during orthopedic procedures. Flexibility creates value$$$$$
    $5++
  • R
    RockJaw
    This site publishes the Premarket Approvals every Monday for medical devices for the prior week. You can search to do more analysis on timing by using date ranges. A lot of these are for device changes. My estimate is end of February since it is not as complex as lot of the products but some went the full 180 days. So Getty up UEEC and the FDA!! https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
    Premarket Approval (PMA)
    www.accessdata.fda.gov
  • A
    Andrew
    In order to get and keep top talent Unites Health has to extend the management and employees the option to bet on the come, believing that their hard work will improve the company performance and attract a buyer at much higher price. UEEC is prime for purchase in whole or by multiple buyers in different fields. I believe final FDA Approval is just weeks away. Time for someone to make those company options pay off for everyone.
    Bullish
  • R
    RockJaw
    Looks like they received FDA quality control input and have responded back on Sunday.
    https://www.clinicaltrials.gov/ct2/show/results/NCT03654560?term=hemostyp&rank=1
    Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting - No Study Results Posted.
    Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting - No Study Results Posted.
    www.clinicaltrials.gov
  • f
    f
    I was told their Hemostyp works better in the trial stage than the similar one on the market from J & J. A lot of companies get bought out over one or few patents??
  • R
    Rainer
    I’ve had this stock for four years can’t wait for the day where it pops
Advertisement
Advertisement